Xenon Pharmaceuticals Inc. - Common Shares (XENE)

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine franchise by Pfizer Inc. (NYSE: PFE) in 2022, the "new" Biohaven—often called Biohaven 2.0—is grappling with the harsh realities of clinical-stage drug development. The [...]

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Soleno just turned profitable for the first time—right as a major fund made its move.

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.